Which one is better, Imatinib or Ripretinib?

The treatment of gastrointestinal stromal tumors has become an important model for the development of molecular targeted therapy for solid tumors. The success of imatinib has made it a durable first-line treatment for both early- and late-stage disease, but imatinib resistance inevitably emerges, leading to the need for further treatment. Ripretinib is an oral switch-controlled tyrosine kinase inhibitor for the treatment of patients with gastrointestinal stromal tumors (GIST), specifically developed to target primary and secondary KIT and PDGFRα resistance mutations. It is the first drug to be approved as fourth-line therapy for special conditions previously treated with at least 3 other kinase inhibitors.